CDX-011

DRUG2 trials

Sponsors

Celldex Therapeutics

Conditions

Breast CancerMetastatic gpNMB Over-expressing Triple Negative Breast Cancer

Phase 2

A Study of CDX-011 (CR011-vcMMAE) in Patients With Advanced GPNMB-expressing Breast Cancer

CompletedNCT01156753

Celldex TherapeuticsBreast Cancer

Start: 2010-07-31End: 2012-11-30Updated: 2017-07-02

Study of Glembatumumab Vedotin (CDX-011) in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer

CompletedNCT01997333

Celldex TherapeuticsMetastatic gpNMB Over-expressing Triple Negative Breast Cancer

Start: 2013-11-30End: 2018-08-07Updated: 2019-03-08

Related Papers

Drug-Resistant TNBC

Oncology Times2018-02-09

Abstract 5032: Glycoprotein NMB (gpNMB) overexpression is prevalent in human cancers: pancreatic cancer, non-small cell lung cancer, head and neck cancer, and osteosarcoma

Cancer Research2016-07-155 citations

Expression patterns of gpNMB in breast cancer (BC): Retrospective evaluation of tumor tissue from the phase II EMERGE study.

Journal of Clinical Oncology2015-10-011 citations

METRIC: A randomized international study of the antibody-drug conjugate glembatumumab vedotin (GV or CDX-011) in patients (pts) with metastatic gpNMB-overexpressing triple-negative breast cancer (TNBC).

Journal of Clinical Oncology2015-05-209 citations